Effect of Original Peptide Derivatives of Galantamine on Passive Avoidance in Mice

I I Kostadinova; N D Danchev; L T Vezenkov; D S Tsekova; V V Rozhanets

doi:10.1007/s10517-020-05032-z

Effect of Original Peptide Derivatives of Galantamine on Passive Avoidance in Mice

Bull Exp Biol Med. 2020 Dec;170(2):200-202. doi: 10.1007/s10517-020-05032-z. Epub 2020 Dec 3.

Authors

I I Kostadinova¹, N D Danchev², L T Vezenkov³, D S Tsekova³, V V Rozhanets⁴

Affiliations

¹ Department of Pharmacology, Pharmacotherapy, and Toxicology, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria. [email protected].
² Department of Pharmacology, Pharmacotherapy, and Toxicology, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria.
³ Department of Organic Chemistry, University of Chemical Technology and Metallurgy, Sofia, Bulgaria.
⁴ Laboratory of Analytical Toxicology, National Scientific Centre of Narcology - Affiliated Branch of V. P. Serbsky National Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation, Moscow, Russia.

PMID: 33269452
DOI: 10.1007/s10517-020-05032-z

Abstract

The effect of original peptide derivatives of galantamine on scopolamine-induced memory impairment in mice was assessed using the passive avoidance test over 12 days. It was found that some galantamine derivatives administered in a dose of ¹/₂₀LD₅₀ improved the memory in experimental mice, especially on days 5-12 of the experiment.

Keywords: Alzheimer’s disease; galantamine; passive avoidance; peptide derivatives of galantamine; scopolamine.

MeSH terms

Alzheimer Disease / drug therapy
Animals
Avoidance Learning / drug effects*
Behavior, Animal
Disease Models, Animal
Galantamine / pharmacology*
Learning / drug effects
Male
Memory / drug effects
Memory Disorders / drug therapy
Mice
Peptides / chemistry
Peptides / pharmacology*
Scopolamine / pharmacology*

Substances

Peptides
Galantamine
Scopolamine